A Population-Based Assessment of Myocarditis Following mRNA COVID-19 booster Vaccination Among Adult Recipients

[1]  B. Fireman,et al.  Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States , 2022, Annals of Internal Medicine.

[2]  Jie Fang,et al.  Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system , 2022, Frontiers in Immunology.

[3]  Manfred S. Green,et al.  Myocarditis After BNT162b2 COVID-19 Third Booster Vaccine in Israel , 2022, Circulation.

[4]  K. Khunti,et al.  Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex , 2022, Circulation.

[5]  L. Hartling,et al.  Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review , 2022, BMJ.

[6]  R. Nayak,et al.  Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults , 2022, International Journal of Cardiology.

[7]  Yuehua Wu,et al.  Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases , 2022, The Lancet.

[8]  T. Härkänen,et al.  SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents , 2022, JAMA cardiology.

[9]  E. Glassberg,et al.  Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel. , 2022, JAMA.

[10]  E. Woo,et al.  Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022 , 2022, MMWR. Morbidity and mortality weekly report.